As of November 7, 2026, Vir Biotechnology, Inc. is a publicly traded company (Nasdaq: VIR). The largest holder reporting an active stake on Schedule 13D is ARCH Venture Fund IX, L.P., at 7.3%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include BlackRock (12.4%), Vanguard (6.85%), SB Investment Advisers (UK) Limited (6.5%) (Schedule 13D/A, November 6, 2026).
Is this your company?
About to sign with, pay or invest in Vir Biotechnology, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Vir Biotechnology, Inc. a real, registered company?
- Vir Biotechnology, Inc. files with the SEC under CIK 1706431 (its SEC filings).
- Its shares are listed under the ticker VIR on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Vir Biotechnology, Inc. in our court records and SEC 8-K records (as of 2026-11-07).
- Leadership changes: the latest reported is Brent Sabatini, Chief Accounting Officer (Form 8-K filed 2026-07-24). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names ARCH Venture Fund IX, L.P. (filed 2026-11-06).
Who are Vir Biotechnology, Inc.'s owners and officers?
Vir Biotechnology, Inc.: incorporated in Delaware; business address in San Francisco, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13D/A, 2026-11-06).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-11-06 | Arch Venture Fund Ix, L.P. | 7.3% |
| Schedule 13G/A, 2026-10-27 | Blackrock, Inc. | 12.4% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 5.9% |
| Schedule 13G/A, 2026-07-31 | Vanguard Portfolio Management | 6.85% |
| Schedule 13G/A, 2026-05-15 | Sb Investment Advisers (Uk) Limited | 6.5% |
| Schedule 13G, 2026-04-29 | Vanguard Portfolio Management | 5.79% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13D/A, 2026-03-03 | Arch Venture Fund Ix, L.P. | 8.5% |
| Schedule 13G/A, 2026-02-17 | Sb Investment Advisers (Uk) Limited | 9.4% |
Questions about who owns Vir Biotechnology, Inc.
Who owns Vir Biotechnology, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Vir Biotechnology, Inc.: Blackrock, Inc. (12.4%, Schedule 13G/A, filed 2026-10-27), Arch Venture Fund Ix, L.P. (7.3%, Schedule 13D/A, filed 2026-11-06), Vanguard Portfolio Management (6.85%, Schedule 13G/A, filed 2026-07-31), Sb Investment Advisers (Uk) Limited (6.5%, Schedule 13G/A, filed 2026-05-15) and State Street Corporation (5.9%, Schedule 13G, filed 2026-08-07).
Who are the largest shareholders of Vir Biotechnology, Inc.?
By the share each holder's latest filing reports, the largest holders of Vir Biotechnology, Inc. on this page are Blackrock, Inc. (12.4%), Arch Venture Fund Ix, L.P. (7.3%) and Vanguard Portfolio Management (6.85%).
When did Blackrock, Inc. buy into Vir Biotechnology, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2026-10-27, reporting 12.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Vir Biotechnology, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Vir Biotechnology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vir Biotechnology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-24 | Brent Sabatini | Chief Accounting Officer | appointed | 2026-08-03 |
| Form 8-K, 2026-05-28 | Saira Ramasastry | Director | departed | 2026-05-26 |
Which insiders own Vir Biotechnology, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- SB Investment Advisers (UK) Ltd., a 10% owner: 13,728,924 shares (8.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-03).
- SVF Endurance (Cayman) Ltd, a 10% owner: 13,728,924 shares (8.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-03).
- Softbank Vision Fund (AIV M1) L.P., a 10% owner: 13,728,924 shares (8.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-03).
- , a director: 1,476,439 shares (0.86% of shares outstanding), 698,239 held directly and 778,200 indirectly (Form 4, 2025-02-25).
- , a director: 1,078,391 shares (0.63% of shares outstanding) (Form 4, 2026-05-04).
Shares outstanding: 171,270,773 as of 2026-10-28, from the company's latest SEC cover page.
How much has Vir Biotechnology, Inc. raised?
No fundraising or offering filing from Vir Biotechnology, Inc. is on file with us.
Keep reading
More on Vir Biotechnology, Inc. and the records around it.
Vir Biotechnology, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Jul 2026
Companies that share a holder
- ARCH Venture Fund IX, L.P. also filed stake reports on 2 other companies: Sana Biotechnology, Inc. (Aug 2026), Lyell Immunopharma, Inc. (May 2026)
- SB Investment Advisers (UK) Limited also filed stake reports on 5 other companies: Energy Vault Holdings, Inc. (May 2026), Compass, Inc. (Feb 2026), Roivant Sciences Ltd. (Feb 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ACADIA PHARMACEUTICALS INC (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/vir-biotechnology